



an Open Access Journal by MDPI

TRPA1 Receptor as a Potential Therapeutic Target in Pain, Inflammation and Neurodegeneration

Guest Editors:

Prof. Erika Pintér

Department of Pharmacology and Pharmacotherapy, Medical School University of Pecs, Pecs, Hungary

Prof. Dr. Susan D. Brain

School of Cardiovascular & Metabolic Medicine and Sciences, King's College, London, UK

Dr. Romina Nassini

Department of Health Sciences, Clinical Pharmacology Unit, University of Florence, 50139 Florence, Italy

Deadline for manuscript submissions:

closed (31 March 2022)

Message from the Guest Editors

TRPA1 can be triggered by endogenous compounds generated during tissue injury and inflammation. Therefore, recent trends in drug development consider TRPA1 as a novel potential drug target for pain killers and anti-inflammatory drug candidates.

The purpose of this Special Issue is to host research and review papers providing evidence that TRPA1 receptor could be considered as a promising drug target in the treatment of pain, inflammation or degenerative disorders.

Areas of interest include, but are not limited to:

- Identification of TRPA1 as a potential drug target
- Design of novel TRPA1 specific ligands
- The role of TRPA1 in pain and inflammation
- Expression pattern and function of TRPA1 in the CNS
- The role of TRPA1 in neurodegeneration
- TRPA1-mediated effects of sulfide compounds
- TRPA1 receptor in skin diseases.
- The role of TRPA1 as a regulatory molecule.



mdpi.com/si/66793



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us

Pharmaceuticals Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com